The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation
Frick M, Darpö B, Ostergren J, Rosenqvist M
European heart journal · 9 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2000-07-15 · Eur Heart J · vol. 21 · número 14 · págs. 1177–1185
- Editorial
- Oxford University Press
- Citado
- 23 citas · más que el 87% de estudios similares · 1.9× el promedio de su campo
- Referencias
- 35 trabajos
- Acceso
- De pago
- Áreas de investigación
- Atrial Fibrillation Management and Outcomes · Cardiac electrophysiology and arrhythmias · Cardiac Arrhythmias and Treatments
- Palabras clave
- persistent atrial fibrillation, oral magnesium, sotalol, electrical cardioversion, atrial fibrillation recurrence, sinus rhythm maintenance, paroxysmal atrial fibrillation
- MeSH
- humans, atrial fibrillation, recurrence, magnesium hydroxide, sotalol, anti-arrhythmia agents, electrocardiography, electric countershock, administration, oral, double-blind method, safety, heart rate, adult, aged, aged, 80 and over, middle aged, female, male
1 autor
- Mats Frick🇸🇪 · autor de correspondenciaStockholm South General Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Aims
To determine whether magnesium given orally decreases the recurrence rate of atrial fibrillation after elective direct current cardioversion of persistent atrial fibrillation.
Methods and results
Consecutive outpatients were randomized to treatment with oral magnesium (10.3 mmol) or placebo twice daily in a double-blind fashion. Two groups were studied; magnesium study: 170 patients with atrial fibrillation persistent for >1 month, scheduled for their first direct current cardioversion. No concomitant antiarrhythmic drugs of class I or III were allowed. Sotalol and magnesium study: 131 patients with recurrence of persistent atrial fibrillation after previous direct current cardioversion, or a history of paroxysmal atrial fibrillation, treated with sotalol. Patients were followed until recurrence of atrial fibrillation or for at least 6 months. Magnesium study: at cardioversion 67 of 85 (79%) in the placebo group and 64 of 85 (75%) in the magnesium group had converted to sinus rhythm. At the end of the study, with a follow-up of 6 to 42 months, 15% of patients in the placebo group and 19% of patients in the magnesium group remained in sinus rhythm (Log rank test: P=0.37). Sotalol and magnesium study: pharmacological conversion to sinus rhythm, after oral treatment, was achieved in 34 of 131 (26%) patients. Sinus rhythm, with or without cardioversion, was restored in 89% and 85% of the patients in the placebo and magnesium groups, respectively. At the end of the study, with a follow-up of 6 to 42 months, 37% of patients in the placebo group and 30% of patients in the magnesium group remained in sinus rhythm (Log rank test: P=0.64).
Conclusion
In patients with persistent atrial fibrillation, oral treatment with magnesium alone or as an adjuvant to sotalol, does not influence the recurrence rate of atrial fibrillation after elective cardioversion.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.